Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMP-SMX vs Clindamycin for Invasive MRSA in Children
NCT06982105Phase 4Recruiting
- Sponsor
- Indiana University
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trimethoprim + sulfamethoxazole in Staphylococcus aureus infection (2 arms), sponsored by Indiana University. Primary endpoint: Treatment Success at 6 months. Started May 2025; status: recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT06982105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982105.